Browse EX-10 agreements

Amendment No. 3 

To 

Executive Employment Agreement

 

This Amendment No. 3 to the Executive Employment Agreement, dated as of March 1, 2025, between Functional Brands Inc., a Delaware corporation, and its subsidiaries (the “Company”), and Eric Gripentrog, an individual having an address at 14200 NE Riverbend Drive, Battle Ground, Washington 98604 (the “Executive”) (as amended prior hereto, the “Agreement”), is dated as of June 29, 2026 (the “Amendment”).

 

Whereas, pursuant to the Agreement the Executive was retained by the Company to serve as its Chief Executive Officer (“CEO”);

 

Whereas, Section 2.4(a) of the Agreement, as amended by Amendment No. 1 thereto, provides for a performance equity award of restricted stock units (“RSUs”) in the aggregate value of $500,000;

 

Whereas, the Company and the Executive wish to amend the Agreement to remove the RSU award provided under Section 2.4(a) and to replace it with a grant of options to purchase shares of the Company’s common stock;

…

FUNCTIONAL BRANDS INC.

 

2026 EQUITY INCENTIVE PLAN

 

NOTICE OF STOCK OPTION GRANT AND STOCK OPTION AGREEMENT

 

Functional Brands Inc., a Delaware corporation (the “Company”), hereby grants to the Participant named below (the “Participant”) an option (the “Option”) to purchase the number of shares of the Company’s Common Stock set forth below, at the exercise price set forth below, subject to the terms and conditions of the Functional Brands Inc. 2026 Equity Incentive Plan (the “Plan”) and this Notice of Stock Option Grant and Stock Option Agreement (together, this “Agreement”). Capitalized terms used but not defined herein have the meanings given to them in the Plan.

 

NOTICE OF GRANT

 

Participant:

Eric Gripentrog

Address:

14200 NE Riverbend Drive, Battle Ground, Washington 98604

Date of Grant:

June 29, 2026

Vesting:

Fully vested and exercisable in full as of the Date of Grant

Total Number of Shares Subject to the Option:

3,500,000 shares of Common Stock

Exercise Price per Share:

…

INDEMNIFICATION AGREEMENT

This Indemnification Agreement (the “Agreement”) is made as of [ ], by and between Kartoon Studios, Inc., a Nevada corporation (the “Company”), and [________________] (“Indemnitee”).

 

WHEREAS, Indemnitee is [a director/an officer] of the Company [/the Company expects Indemnitee to join the Company as [a director/an officer]];

 

WHEREAS, both the Company and Indemnitee recognize the increased risk of litigation and other claims being asserted against directors and officers of public companies;

 

WHEREAS, the Company desires to attract and continue to retain the services of highly qualified individuals, such as Indemnitee, to serve as officers and directors of the Company and to indemnify its officers and directors so as to provide them with the maximum protection permitted by law;

…

AMENDMENT TO SHARE PURCHASE AGREEMENT

 

This Amendment to Share Purchase Agreement (this “Amendment”) is made as of this June 29, 2026 by and among AUSTRALIAN OILSEEDS HOLDINGS LIMITED (the “Purchaser”), Hailing Fan (the “Seller”) and RENTBUDDYUK Limited, a company incorporated under the laws of the United Kingdom (the “Target Company”). The Purchaser, the Seller and the Target Company are referred to herein collectively as the “Parties” and individually as a “Party”.

 

WHEREAS, the Purchaser and the Seller entered into that certain share purchase agreement dated as of April 24, 2026 (the “Share Purchase Agreement”), pursuant to which, among other things, the Purchaser desired to acquire from the Seller, and the Seller desires to sell to the Purchaser 5,100 ordinary shares of the Target Company;

…

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

 

June 30, 2026

 

Holder of Common Stock Purchase Warrants

 

Re:

Inducement Offer to Exercise Common Stock Purchase Warrants

 

Dear Holder:

 

Creative Medical Technology Holdings, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and (ii) a reduction in the Exercise Price (as defined in the respective Existing Warrants (as defined below)) , in consideration for your cash exercise of all of the Existing Warrants at the Reduced Exercise Price (as defined below) of $1.60 per share of the warrants set forth on Exhibit A hereto (the “Existing Warrants”) held by you as set forth on the signature page hereto. The resale of the shares of Common Stock underlying the Existing Warrants (the “Existing Warrant Shares”) has been registered pursuant to the registration statement on Form S-3 (File No. 333-291713) (the “Registration Statement”). The Registration Sta

…

AMENDMENT TO Ordinary SHARE PURCHASE WARRANT

This AMENDMENT TO ORDINARY SHARE PURCHASE WARRANT (this “Amendment”) is entered into as of June 17, 2026, by and between IceCure Medical Ltd., a company organized under the laws of the State of Israel (the “Company”), and Armistice Capital Master Fund Ltd. (the “Holder”).

WHEREAS, the Company issued to the Holder those certain Series B Ordinary Share Purchase Warrants (the “Series B Warrants”) and Series C Ordinary Share Purchase Warrants (the “Series C Warrants” and, together with the Series B Warrants, the “Original Warrants”) on March 27, 2026;

WHEREAS, the Original Warrants are exercisable, in the aggregate, for up to 266,666 ordinary shares of the company, no par value, (the “Ordinary Shares”), at a per share exercise price equal to $16.50;

WHEREAS, pursuant to Section 5(l) of the Original Warrants, the Original Warrants may be modified or amended, or the provisions thereof waived, with the written consent of the Company and the Holder; and

…

Document

Certain information in this document has been omitted and replaced with “[*****]”. Such identified information has been omitted from this document because it is not material and is of the type that the registrant treats as private or confidential.

MASTER DEFINITIONS AND COMMON TERMS AGREEMENT

        DATED 26 JUNE 2026

between

BNP PARIBAS S.A., DUBLIN BRANCH as Master Purchaser

TD SYNNEX IRELAND RECEIVABLES I DESIGNATED ACTIVITY COMPANY as Final Purchaser and Issuer

BNP PARIBAS

BANCO SANTANDER S.A.

CREDIT AGRICOLE CORPORATE & INVESTMENT BANK as Senior Notes Subscribers

BNP PARIBAS

as Lead Arranger

EACH ENTITY LISTED IN SCHEDULE 2

as a Seller, as a Servicer and as a Risk Retention Holder

TD SYNNEX UK ACQUISITION LIMITED

as Programme Servicer, Junior Notes Subscriber and PPN Holder

BNP PARIBAS, LONDON BRANCH

as Account Bank

CSC CAPITAL MARKETS (IRELAND) LIMITED

as Corporate Services Provider, Back-Up Cash Manager and Registrar

FIS CAPITAL MARKETS UK LIMITED

as Calculation Agent

TD SYNNEX UK ACQUISITION LIMITED

as Cash Manager

…

Document

Certain information in this document has been omitted and replaced with “[*****]”. Such identified information has been omitted from this document because it is not material and is of the type that the registrant treats as private or confidential.

MASTER TRANSFER AND SERVICING AGREEMENT

DATED 26 JUNE 2026

between

BNP PARIBAS S.A., DUBLIN BRANCH as Master Purchaser

EACH ENTITY LISTED IN SCHEDULE 1

as Seller and as Servicer

TD SYNNEX UK ACQUISITION LIMITED

as Programme Servicer

TD SYNNEX UK ACQUISITION LIMITED

as Junior Notes Subscriber

CSC TRUSTEES LIMITED

as Security Trustee

and

TD SYNNEX CORPORATION

as Guarantor

---

TABLE OF CONTENTS

CHAPTER I. GENERAL PROVISIONS    Page

CHAPTER I. GENERAL PROVISIONS    5

1.    DEFINITIONS    5

2.    [NOT USED]    6

3.    SEVERAL LIABILITY OF THE SELLERS    6

4.    PURPOSE    7

5.    DURATION OF THIS AGREEMENT    7

CHAPTER II. PROGRAMME SERVICER    8

6.    MANDATE OF THE PROGRAMME SERVICER    8

7.    DURATION AND TERMINATION OF THE APPOINTMENT OF THE PROGRAMME SERVICER    10

…

Document

Certain information in this document has been omitted and replaced with “[*****]”. Such identified information has been omitted from this document because it is not material and is of the type that the registrant treats as private or confidential.

SENIOR VARIABLE FUNDING NOTES FACILITY AGREEMENT

DATED 26 JUNE 2026

between

TD SYNNEX IRELAND RECEIVABLES I DESIGNATED ACTIVITY COMPANY as Issuer

BNP PARIBAS

BANCO SANTANDER S.A.

CREDIT AGRICOLE CORPORATE AND INVESTMENT BANK as Senior Notes Subscribers

TD SYNNEX UK ACQUISITION LIMITED Programme Servicer

BNP PARIBAS as Lead Arranger

CSC TRUSTEES LIMITED as Security Trustee

TD SYNNEX UK ACQUISITION LIMITED as Cash Manager

CSC CAPITAL MARKETS (IRELAND) LIMITED as Back-Up Cash Manager

and

CSC CAPITAL MARKETS (IRELAND) LIMITED as Registrar

---

TABLE OF CONTENTS

Page

…

Exhibit 10.1

 

First Amendment to Registration Rights Agreement

 

This First Amendment to the Registration Rights Agreement (the “Amendment”), dated as of June 23, 2026, is made by and between BNB Plus Corp., a Delaware corporation (“Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). The parties hereto are referred to collectively as the “Parties” and individually as a “Party”.

 

Whereas, the Parties have entered into that certain Registration Rights Agreement (the “Agreement”) dated as of May 26, 2026;

 

Whereas, pursuant to Section 6(b) of the Agreement, the Parties desire to amend the Agreement to extend the Filing Date (as defined in the Agreement) as more fully described herein; and

 

Whereas, the Purchasers hereto hold 50.1% or more of the Registrable Securities.

…

Document

Exhibit 10.01

Certain confidential information contained in this document, marked by [* * *], has been omitted pursuant to Item 601 (b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) the type of information that the registrant treats as private or confidential.

CAPSOVISION, INC.

AMENDED AND RESTATED CONSULTING AGREEMENT

    This Amended and Restated Consulting Agreement (“Agreement”) is entered into as of July 2, 2026 (the “Effective Date”) by and between CapsoVision, Inc., a Delaware corporation (the “Company”), and Joanne C Imperial MD (“Consultant”), with residence at [***].

WHEREAS, the Company and Consultant previously entered into that certain Consulting Agreement, dated as of July 23, 2025 (the “Original Agreement”), pursuant to which Consultant has provided consulting services to the Company as an independent contractor;

…

Document

Exhibit 10.02

Certain confidential information contained in this document, marked by [* * *], has been omitted pursuant to Item 601 (b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) the type of information that the registrant treats as private or confidential.

CAPSOVISION, INC.

CONSULTING AGREEMENT

    This Consulting Agreement (“Agreement”) is entered into as of July 2, 2026 (the “Effective Date”) by and between CapsoVision, Inc., a Delaware corporation (the “Company”), and David S. Shields, M.D. (“Consultant”), with residence at [***]. The Company desires to retain Consultant as an independent contractor to perform consulting services for the Company, and Consultant is willing to perform such services, on the terms described below. In consideration of the mutual promises contained herein, the parties agree as follows:

…